Background: HER2 antibody-drug conjugates are reshaping the conventional HER2 status
dichotomy, heightening expectations in the realm of HER2 status assessment and its …

Background: The definition of HER2-low breast cancer from clinical trials of antibody-
conjugated drugs (ADCs) relies on immunohistochemistry scoring (IHC). However, in daily …

In clinical trials evaluating antibody-conjugated drugs (ADCs), HER2-low breast cancer is
defined through protein immunohistochemistry scoring (IHC) 1+ or 2+ without gene …

Currently, the human epidermal growth factor receptor 2 (HER2) status of breast cancer is
classified dichotomously as negative or positive to select patients for HER2-targeted …

Growing evidence suggests a clear role of the host immune system in HER2+ breast cancer.
In addition, HER2+ breast cancer is generally considered more immunogenic than hormone …

Simple Summary Breast cancer is the most common cancer in women. Approximately 15%
of breast cancers harbour an amplification of the ERBB2 gene and/or an overexpression of …

The HER2 receptor is amplified or overexpressed in approximately 20% of all breast
cancers, but despite significant efforts of the clinical research community and a growing …

Introduction HER2-positive breast cancer (BC) is a heterogeneous group of aggressive
breast cancers, the prognosis of which has greatly improved since the introduction of …

Simple Summary Classical clinical research has been developed according to
immunohistochemical breast cancer subtypes, instead of designing trials specifically for …

HER2 status in breast cancer is assessed to select patients eligible for targeted therapy with
anti-HER2 therapies. According to the American Society of Clinical Oncology (ASCO) and …